Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-07-06 Director's Dealing
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as directors or officers. It details transactions in the company's shares by an executive (Robert B. Ford, Executive Vice President) including dates, amounts, and prices. This type of filing is specifically related to insider trading disclosures and personal share transactions by company directors and executives. It is not a financial report, earnings release, or any other type of corporate report. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on insider share transactions, confirming this classification with high confidence.
2016-07-06 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as directors or officers. It includes details of share transactions by an executive (Heather L. Mason) of Abbott Laboratories. This type of filing reports insider trades and is not a financial report, earnings release, or any other type of corporate report. Therefore, it fits the category of Director's Dealing (DIRS). The document length is about 4006 characters, consistent with a typical Form 4 filing. No other report types or announcements are indicated.
2016-07-06 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as directors and officers. It details transactions in the company's shares by a senior vice president, including acquisitions and disposals. This type of filing is specifically related to insider trading disclosures and personal share transactions by company directors and executives. It is not a financial report, earnings release, or any other type of corporate report. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content confirm it is not an announcement or a report publication but the actual Form 4 filing.
2016-07-06 English
FORM 4 -
Director's Dealing
2016-07-05 English
FORM 4 -
Director's Dealing
2016-07-05 English
FORM 4 -
Director's Dealing
2016-07-05 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.